Danxiang Chen1, Lingli Jin1, Yiying Xu1, Adheesh Bhandari1, Ouchen Wang1. 1. Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University Nan Bai Xiang Street, Wenzhou 325006, Zhejiang, People's Republic of China.
Abstract
BACKGROUND: Evidence on the effectiveness of ErbB inhibitor interventions for women with triple-positive breast cancer (TPBC) is scarce. Exposure to hormone receptors was reported to eclipse targeted intervention effectiveness. Here, we aimed to explore the optimum targeted regimen for TPBC. METHODS: We conducted a thorough search of the literature focusing on neoadjuvant targeted therapy with both hormone receptor-positive and HER2 (ErbB2)-positive patients and performed a network meta-analysis comparing the regimens using a random-effects model. The rate of pathological complete response (pCR) (ypT0/is) was the primary outcome. The odds ratio (OR) with 95% confidence interval (CI) was used to assess the association among twelve regimens. RESULTS: Thirteen studies meeting the inclusion criteria were included. Significantly more TPBC patients receiving ado-trastuzumab emtansine plus lapatinib experienced pCR events than other patients. In the high-performance ranking of the twelve regimens, ado-trastuzumab emtansine plus lapatinib (TDM-1+L) ranked top, followed by ado-trastuzumab emtansine (TDM-1), trastuzumab plus carboplatin, taxanes and pertuzumab (TCHP), trastuzumab plus docetaxel and lapatinib (THL), trastuzumab, taxanes and pertuzumab (THP), ado-trastuzumab emtansine plus pertuzumab (TDM1+P), trastuzumab plus taxanes (TH), trastuzumab plus taxanes and neratinib, taxanes plus pertuzumab (HP), taxanes and neratinib (HN), trastuzumab plus lapatinib (TL), trastuzumab plus pertuzumab (TP) in sequence. CONCLUSION: Double-targeted therapy in chemotherapy-based regimens was associated with better pCR than single-targeted therapy, and TDM-1+L stood out. For either single-targeted or double-targeted therapies, regimens free of chemotherapy were always worse than those with targeted therapy. Our data support guidelines that recommend combinations of chemotherapies plus targeted therapies in the neoadjuvant setting for early TPBC. AJTR
BACKGROUND: Evidence on the effectiveness of ErbB inhibitor interventions for women with triple-positive breast cancer (TPBC) is scarce. Exposure to hormone receptors was reported to eclipse targeted intervention effectiveness. Here, we aimed to explore the optimum targeted regimen for TPBC. METHODS: We conducted a thorough search of the literature focusing on neoadjuvant targeted therapy with both hormone receptor-positive and HER2 (ErbB2)-positive patients and performed a network meta-analysis comparing the regimens using a random-effects model. The rate of pathological complete response (pCR) (ypT0/is) was the primary outcome. The odds ratio (OR) with 95% confidence interval (CI) was used to assess the association among twelve regimens. RESULTS: Thirteen studies meeting the inclusion criteria were included. Significantly more TPBC patients receiving ado-trastuzumab emtansine plus lapatinib experienced pCR events than other patients. In the high-performance ranking of the twelve regimens, ado-trastuzumab emtansine plus lapatinib (TDM-1+L) ranked top, followed by ado-trastuzumab emtansine (TDM-1), trastuzumab plus carboplatin, taxanes and pertuzumab (TCHP), trastuzumab plus docetaxel and lapatinib (THL), trastuzumab, taxanes and pertuzumab (THP), ado-trastuzumab emtansine plus pertuzumab (TDM1+P), trastuzumab plus taxanes (TH), trastuzumab plus taxanes and neratinib, taxanes plus pertuzumab (HP), taxanes and neratinib (HN), trastuzumab plus lapatinib (TL), trastuzumab plus pertuzumab (TP) in sequence. CONCLUSION: Double-targeted therapy in chemotherapy-based regimens was associated with better pCR than single-targeted therapy, and TDM-1+L stood out. For either single-targeted or double-targeted therapies, regimens free of chemotherapy were always worse than those with targeted therapy. Our data support guidelines that recommend combinations of chemotherapies plus targeted therapies in the neoadjuvant setting for early TPBC. AJTR
Authors: Harpreet Singh; Amanda J Walker; Laleh Amiri-Kordestani; Joyce Cheng; Shenghui Tang; Pamela Balcazar; Kimberly Barnett-Ringgold; Todd R Palmby; Xianhua Cao; Nan Zheng; Qi Liu; Jingyu Yu; William F Pierce; Selena R Daniels; Rajeshwari Sridhara; Amna Ibrahim; Paul G Kluetz; Gideon M Blumenthal; Julia A Beaver; Richard Pazdur Journal: Clin Cancer Res Date: 2018-03-09 Impact factor: 12.531
Authors: André Robidoux; Gong Tang; Priya Rastogi; Charles E Geyer; Catherine A Azar; James N Atkins; Louis Fehrenbacher; Harry D Bear; Louis Baez-Diaz; Shakir Sarwar; Richard G Margolese; William B Farrar; Adam M Brufsky; Henry R Shibata; Hanna Bandos; Soonmyung Paik; Joseph P Costantino; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark Journal: Lancet Oncol Date: 2013-10-04 Impact factor: 41.316
Authors: A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés Journal: Ann Oncol Date: 2013-05-22 Impact factor: 32.976
Authors: Laleh Amiri-Kordestani; Gideon M Blumenthal; Qiang Casey Xu; Lijun Zhang; Shenghui W Tang; Linan Ha; Wendy C Weinberg; Bo Chi; Reyes Candau-Chacon; Patricia Hughes; Anne M Russell; Sarah Pope Miksinski; Xiao Hong Chen; W David McGuinn; Todd Palmby; Sarah J Schrieber; Qi Liu; Jian Wang; Pengfei Song; Nitin Mehrotra; Lisa Skarupa; Kathleen Clouse; Ali Al-Hakim; Rajeshwari Sridhara; Amna Ibrahim; Robert Justice; Richard Pazdur; Patricia Cortazar Journal: Clin Cancer Res Date: 2014-05-30 Impact factor: 12.531
Authors: Samuel A Jacobs; André Robidoux; Jame Abraham; José Manuel Pérez-Garcia; Nicla La Verde; James M Orcutt; Marina E Cazzaniga; Fanny Piette; Silvia Antolín; Elena Aguirre; Javier Cortes; Antonio Llombart-Cussac; Serena Di Cosimo; Rim S Kim; Huichen Feng; Corey Lipchik; Peter C Lucas; Ashok Srinivasan; Ying Wang; Nan Song; Patrick G Gavin; April D Balousek; Soonmyung Paik; Carmen J Allegra; Norman Wolmark; Katherine L Pogue-Geile Journal: Breast Cancer Res Date: 2019-12-03 Impact factor: 6.466